NCT05266729View on ClinicalTrials.gov

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

December 28, 2022

Study Completion Date

February 20, 2023

Conditions
Moderate or Severe Submental Fullness
Interventions
DRUG

Polyene Phosphatidylcholine

Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.

DRUG

Placebo

Phosphate buffered saline placebo for injection

Trial Locations (1)

06973

Chung Ang University Hospital, Seoul

All Listed Sponsors
lead

AMIpharm Co., Ltd.

INDUSTRY